Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
60
NXG.V Quote, Financials, Valuation and Earnings
Last price:
$0.36
Seasonality move
:
3.98%
Day range:
$0.36 - $0.36
52-week range:
$0.25 - $0.45
Dividend yield:
4.17%
P/E ratio:
25.71x
P/S ratio:
1.52x
P/B ratio:
4.29x
Volume:
--
Avg. volume:
22.8K
1-year change:
44%
Market cap:
$25.6M
Revenue:
$17.5M
EPS (TTM):
$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NXG.V
NexgenRx, Inc.
|
-- | -- | -- | -- | -- |
|
APS.TO
Aptose Biosciences, Inc.
|
-- | -$3.92 | -- | -77.82% | $2.41 |
|
ARCH.V
Arch Biopartners, Inc.
|
-- | -- | -- | -- | -- |
|
ENBI.CX
Entheon Biomedical Corp.
|
-- | -- | -- | -- | -- |
|
IOT.V
Innovotech, Inc.
|
-- | -- | -- | -- | -- |
|
MIR.V
MedMira, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NXG.V
NexgenRx, Inc.
|
$0.36 | -- | $25.6M | 25.71x | $0.01 | 4.17% | 1.52x |
|
APS.TO
Aptose Biosciences, Inc.
|
$2.35 | $2.41 | $5.9M | -- | $0.00 | 0% | 23.05x |
|
ARCH.V
Arch Biopartners, Inc.
|
$0.6000 | -- | $40.8M | -- | $0.00 | 0% | -- |
|
ENBI.CX
Entheon Biomedical Corp.
|
$0.08 | -- | $1M | -- | $0.00 | 0% | 2.48x |
|
IOT.V
Innovotech, Inc.
|
$0.18 | -- | $8.2M | 116.67x | $0.00 | 0% | 1.99x |
|
MIR.V
MedMira, Inc.
|
$0.0650 | -- | $45.6M | -- | $0.00 | 0% | 240.57x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NXG.V
NexgenRx, Inc.
|
4.77% | 0.582 | 1.45% | 1.10x |
|
APS.TO
Aptose Biosciences, Inc.
|
-4392.48% | -0.776 | 632.12% | 0.23x |
|
ARCH.V
Arch Biopartners, Inc.
|
-272.64% | 2.282 | 3.22% | 0.00x |
|
ENBI.CX
Entheon Biomedical Corp.
|
-- | 2.350 | -- | 4.47x |
|
IOT.V
Innovotech, Inc.
|
-- | 3.228 | -- | 3.94x |
|
MIR.V
MedMira, Inc.
|
-261.67% | 1.240 | 38.12% | 0.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NXG.V
NexgenRx, Inc.
|
$3.1M | $195.2K | 16.94% | 17.94% | 4.65% | -$2.3M |
|
APS.TO
Aptose Biosciences, Inc.
|
-$152.9K | -$6.8M | -1584.91% | -- | -- | -$10.3M |
|
ARCH.V
Arch Biopartners, Inc.
|
-- | -$1.5M | -- | -- | -- | -$849.9K |
|
ENBI.CX
Entheon Biomedical Corp.
|
-- | -$101K | -74.29% | -74.29% | -- | -$54.2K |
|
IOT.V
Innovotech, Inc.
|
$662.7K | $153.5K | 15.67% | 15.81% | 12.11% | -$160.8K |
|
MIR.V
MedMira, Inc.
|
-$247.8K | -$495.6K | -- | -- | -2022.86% | -$267.7K |
NexgenRx, Inc. vs. Competitors
-
Which has Higher Returns NXG.V or APS.TO?
Aptose Biosciences, Inc. has a net margin of 14.04% compared to NexgenRx, Inc.'s net margin of --. NexgenRx, Inc.'s return on equity of 17.94% beat Aptose Biosciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NXG.VNexgenRx, Inc.74.32% $0.01 $8.7M APS.TOAptose Biosciences, Inc.-- -$2.76 -$602.4K -
What do Analysts Say About NXG.V or APS.TO?
NexgenRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aptose Biosciences, Inc. has an analysts' consensus of $2.41 which suggests that it could grow by 2.41%. Given that Aptose Biosciences, Inc. has higher upside potential than NexgenRx, Inc., analysts believe Aptose Biosciences, Inc. is more attractive than NexgenRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NXG.VNexgenRx, Inc.0 0 0 APS.TOAptose Biosciences, Inc.0 1 0 -
Is NXG.V or APS.TO More Risky?
NexgenRx, Inc. has a beta of 0.465, which suggesting that the stock is 53.49% less volatile than S&P 500. In comparison Aptose Biosciences, Inc. has a beta of 0.152, suggesting its less volatile than the S&P 500 by 84.785%.
-
Which is a Better Dividend Stock NXG.V or APS.TO?
NexgenRx, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 4.17%. Aptose Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexgenRx, Inc. pays 100.67% of its earnings as a dividend. Aptose Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NXG.V or APS.TO?
NexgenRx, Inc. quarterly revenues are $4.2M, which are larger than Aptose Biosciences, Inc. quarterly revenues of --. NexgenRx, Inc.'s net income of $589.8K is higher than Aptose Biosciences, Inc.'s net income of -$7.1M. Notably, NexgenRx, Inc.'s price-to-earnings ratio is 25.71x while Aptose Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexgenRx, Inc. is 1.52x versus 23.05x for Aptose Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NXG.VNexgenRx, Inc.1.52x 25.71x $4.2M $589.8K APS.TOAptose Biosciences, Inc.23.05x -- -- -$7.1M
-
Which has Higher Returns NXG.V or ARCH.V?
Arch Biopartners, Inc. has a net margin of 14.04% compared to NexgenRx, Inc.'s net margin of --. NexgenRx, Inc.'s return on equity of 17.94% beat Arch Biopartners, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NXG.VNexgenRx, Inc.74.32% $0.01 $8.7M ARCH.VArch Biopartners, Inc.-- -$0.02 -$965.8K -
What do Analysts Say About NXG.V or ARCH.V?
NexgenRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Arch Biopartners, Inc. has an analysts' consensus of -- which suggests that it could grow by 483.33%. Given that Arch Biopartners, Inc. has higher upside potential than NexgenRx, Inc., analysts believe Arch Biopartners, Inc. is more attractive than NexgenRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NXG.VNexgenRx, Inc.0 0 0 ARCH.VArch Biopartners, Inc.0 0 0 -
Is NXG.V or ARCH.V More Risky?
NexgenRx, Inc. has a beta of 0.465, which suggesting that the stock is 53.49% less volatile than S&P 500. In comparison Arch Biopartners, Inc. has a beta of 1.561, suggesting its more volatile than the S&P 500 by 56.076%.
-
Which is a Better Dividend Stock NXG.V or ARCH.V?
NexgenRx, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 4.17%. Arch Biopartners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexgenRx, Inc. pays 100.67% of its earnings as a dividend. Arch Biopartners, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NXG.V or ARCH.V?
NexgenRx, Inc. quarterly revenues are $4.2M, which are larger than Arch Biopartners, Inc. quarterly revenues of --. NexgenRx, Inc.'s net income of $589.8K is higher than Arch Biopartners, Inc.'s net income of -$1.6M. Notably, NexgenRx, Inc.'s price-to-earnings ratio is 25.71x while Arch Biopartners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexgenRx, Inc. is 1.52x versus -- for Arch Biopartners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NXG.VNexgenRx, Inc.1.52x 25.71x $4.2M $589.8K ARCH.VArch Biopartners, Inc.-- -- -- -$1.6M
-
Which has Higher Returns NXG.V or ENBI.CX?
Entheon Biomedical Corp. has a net margin of 14.04% compared to NexgenRx, Inc.'s net margin of --. NexgenRx, Inc.'s return on equity of 17.94% beat Entheon Biomedical Corp.'s return on equity of -74.29%.
Company Gross Margin Earnings Per Share Invested Capital NXG.VNexgenRx, Inc.74.32% $0.01 $8.7M ENBI.CXEntheon Biomedical Corp.-- -$0.00 $224.3K -
What do Analysts Say About NXG.V or ENBI.CX?
NexgenRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Entheon Biomedical Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that NexgenRx, Inc. has higher upside potential than Entheon Biomedical Corp., analysts believe NexgenRx, Inc. is more attractive than Entheon Biomedical Corp..
Company Buy Ratings Hold Ratings Sell Ratings NXG.VNexgenRx, Inc.0 0 0 ENBI.CXEntheon Biomedical Corp.0 0 0 -
Is NXG.V or ENBI.CX More Risky?
NexgenRx, Inc. has a beta of 0.465, which suggesting that the stock is 53.49% less volatile than S&P 500. In comparison Entheon Biomedical Corp. has a beta of 1.733, suggesting its more volatile than the S&P 500 by 73.259%.
-
Which is a Better Dividend Stock NXG.V or ENBI.CX?
NexgenRx, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 4.17%. Entheon Biomedical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexgenRx, Inc. pays 100.67% of its earnings as a dividend. Entheon Biomedical Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NXG.V or ENBI.CX?
NexgenRx, Inc. quarterly revenues are $4.2M, which are larger than Entheon Biomedical Corp. quarterly revenues of --. NexgenRx, Inc.'s net income of $589.8K is higher than Entheon Biomedical Corp.'s net income of -$99.7K. Notably, NexgenRx, Inc.'s price-to-earnings ratio is 25.71x while Entheon Biomedical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexgenRx, Inc. is 1.52x versus 2.48x for Entheon Biomedical Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NXG.VNexgenRx, Inc.1.52x 25.71x $4.2M $589.8K ENBI.CXEntheon Biomedical Corp.2.48x -- -- -$99.7K
-
Which has Higher Returns NXG.V or IOT.V?
Innovotech, Inc. has a net margin of 14.04% compared to NexgenRx, Inc.'s net margin of 7.33%. NexgenRx, Inc.'s return on equity of 17.94% beat Innovotech, Inc.'s return on equity of 15.81%.
Company Gross Margin Earnings Per Share Invested Capital NXG.VNexgenRx, Inc.74.32% $0.01 $8.7M IOT.VInnovotech, Inc.52.28% $0.00 $2.8M -
What do Analysts Say About NXG.V or IOT.V?
NexgenRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Innovotech, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that NexgenRx, Inc. has higher upside potential than Innovotech, Inc., analysts believe NexgenRx, Inc. is more attractive than Innovotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NXG.VNexgenRx, Inc.0 0 0 IOT.VInnovotech, Inc.0 0 0 -
Is NXG.V or IOT.V More Risky?
NexgenRx, Inc. has a beta of 0.465, which suggesting that the stock is 53.49% less volatile than S&P 500. In comparison Innovotech, Inc. has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.546%.
-
Which is a Better Dividend Stock NXG.V or IOT.V?
NexgenRx, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 4.17%. Innovotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexgenRx, Inc. pays 100.67% of its earnings as a dividend. Innovotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NXG.V or IOT.V?
NexgenRx, Inc. quarterly revenues are $4.2M, which are larger than Innovotech, Inc. quarterly revenues of $1.3M. NexgenRx, Inc.'s net income of $589.8K is higher than Innovotech, Inc.'s net income of $92.9K. Notably, NexgenRx, Inc.'s price-to-earnings ratio is 25.71x while Innovotech, Inc.'s PE ratio is 116.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexgenRx, Inc. is 1.52x versus 1.99x for Innovotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NXG.VNexgenRx, Inc.1.52x 25.71x $4.2M $589.8K IOT.VInnovotech, Inc.1.99x 116.67x $1.3M $92.9K
-
Which has Higher Returns NXG.V or MIR.V?
MedMira, Inc. has a net margin of 14.04% compared to NexgenRx, Inc.'s net margin of -2684.08%. NexgenRx, Inc.'s return on equity of 17.94% beat MedMira, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NXG.VNexgenRx, Inc.74.32% $0.01 $8.7M MIR.VMedMira, Inc.-1011.43% -$0.00 -$6.6M -
What do Analysts Say About NXG.V or MIR.V?
NexgenRx, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand MedMira, Inc. has an analysts' consensus of -- which suggests that it could grow by 207.69%. Given that MedMira, Inc. has higher upside potential than NexgenRx, Inc., analysts believe MedMira, Inc. is more attractive than NexgenRx, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NXG.VNexgenRx, Inc.0 0 0 MIR.VMedMira, Inc.0 0 0 -
Is NXG.V or MIR.V More Risky?
NexgenRx, Inc. has a beta of 0.465, which suggesting that the stock is 53.49% less volatile than S&P 500. In comparison MedMira, Inc. has a beta of 0.828, suggesting its less volatile than the S&P 500 by 17.213%.
-
Which is a Better Dividend Stock NXG.V or MIR.V?
NexgenRx, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 4.17%. MedMira, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexgenRx, Inc. pays 100.67% of its earnings as a dividend. MedMira, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NXG.V or MIR.V?
NexgenRx, Inc. quarterly revenues are $4.2M, which are larger than MedMira, Inc. quarterly revenues of $24.5K. NexgenRx, Inc.'s net income of $589.8K is higher than MedMira, Inc.'s net income of -$657.6K. Notably, NexgenRx, Inc.'s price-to-earnings ratio is 25.71x while MedMira, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexgenRx, Inc. is 1.52x versus 240.57x for MedMira, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NXG.VNexgenRx, Inc.1.52x 25.71x $4.2M $589.8K MIR.VMedMira, Inc.240.57x -- $24.5K -$657.6K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
